14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LLY vs AVDL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Eli Lilly & Co. (LLY) on higher Unified Composite conviction (62.9/100 BUY vs. 41.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while LLY wins 5–1 across the 6-pillar growth and valuation breakdown. LLY trades at $1,347.11 (26.5x Forward P/E, 51.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin).
Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LLY 41.4/100 SELL) and 0.14β · 2% Vol risk profile, whereas LLY leads top-line expansion (+38.6% YoY revenue growth, 1.28x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LLY vs AVDL. Trailing 12-month operating profitability (LLY 51.2% vs AVDL 2.5%) and valuation multiples (LLY 26.5x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LLY vs AVDL Key Questions & Quantitative Answers
As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Eli Lilly & Co. (LLY) on higher Unified Composite conviction (62.9/100 BUY vs. 41.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples), while LLY wins 5–1 across the 6-pillar growth and valuation breakdown. LLY trades at $1,347.11 (26.5x Forward P/E, 51.2% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LLY 41.4/100 SELL) and 0.14β · 2% Vol risk profile, whereas LLY leads top-line expansion (+38.6% YoY revenue growth, 1.28x PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
LLY leads the Growth & Scale pillar: LLY posts +38.6% YoY revenue growth and +16.3% YoY earnings growth on $86.5B TTM revenue (83.6% gross margin, 51.2% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, LLY generates $86.5B in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, LLY deploys 32.4% of Rev ($28.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.
AVDL screens cheaper on headline valuation multiples. LLY trades at 26.5x Forward P/E, 44.9x Trailing P/E, 1.28x PEG, and 14.4x EV/Revenue (13.5% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LLY (86.0% ROE) versus AVDL (-0.3% ROE) capital efficiency.
In options market volatility and institutional positioning, LLY carries 34.2% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.95x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 36% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.